Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

• Main Authors: Rodolfo Sacco (Author), Vincenzo Messina (Author), Umberto Vespasiani Gentilucci (Author), Luigi Elio Adinolfi (Author), Antonio Ascione (Author), Giorgio Barbarini (Author), Angelo Barlattani (Author), Giuseppe Cariti (Author), Raffaele Cozzolongo (Author), Basilio Fimiani (Author), Ruggiero Francavilla (Author), Caterina Furlan (Author), Giovanni Garrucciu (Author), Vincenzo Iovinella (Author), Luca Rinaldi (Author), Massimo Marignani (Author), Paola Begini (Author), Valeria Pace Palitti (Author), Adriano M Pellicelli (Author), Gaetano Scifo (Author), Antonio Facciorusso (Author), Luca Giacomelli (Author), Aashni Shah (Author), Gaetano Bertino (Author), Serena Perazzo (Author), Giampaolo Bresci (Author), Antonio Izzi (Author)
• Format: Book
• Published: BioExcel Publishing Ltd, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to investigate the effectiveness and safety of the D...